Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

William Schmidt (NPI 1467455386)

Field	Value
Entity Type	Individual
Organization	William Schmidt
Address	1501 Ne Medical Center Dr
City	Bend
State	OR
ZIP	97701
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 24, 2005

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

WILLIAM SCHMIDT is highly focused on oncology infusions and supportive oncology care: the largest single service by revenue is pembrolizumab (J9271) accounting for $877.2K and 64.5% of the provider's Medicare revenue, with additional oncology drugs and chemotherapy administration codes (96413, 96417, G0498, 96365/96367) appearing in the top 25 list. This mix indicates an office-based oncology practice that delivers high-cost immune checkpoint therapy alongside routine chemotherapy infusion and supportive drug administration rather than primarily inpatient or procedure-heavy services.

Revenue is heavily concentrated in a very small number of services: the precomputed top 3 Medicare codes account for 75.6% of total Medicare revenue, showing the practice depends on a few high-revenue oncology drug codes rather than a broad spread of low-cost services. That concentration poses business sensitivity to pricing or utilization changes for those specific drugs.

The provider is effectively single-payer with respect to public programs: lifetime Medicare revenue is $1.4M while there is no Medicaid billing on file. This means Medicare is the sole public payer represented in the record and Medicaid does not contribute to the measurable revenue mix for this clinician.

Competitive standing varies by code: for the practice’s dominant drug J9271 the provider ranks #375 of 1841 (79th percentile), which positions him as a typical but not leading national participant for pembrolizumab administration. By contrast, for office E/M code 99215 the provider ranks #1130 of 145531 (99th percentile) and is described as an “extreme outlier,” indicating unusually high volume of high-complexity outpatient visits relative to national peers.

Several codes show notably high percentile ranks for routine and ancillary services, reflecting steady office throughput: 99214 ranks in the 95th percentile, 85025 and 80053 are in the mid-90s percentiles, and 36415 and 96372 are in the high-90s percentiles for national comparison. These patterns support a model with frequent outpatient encounters, lab draws, and injections that complement infusion-based oncology care.

Some biologic and supportive agents are used at rates that are typical within smaller national cohorts: Q5106 (epoetin biosimilar) and J0897 (denosumab) are described as typical/unremarkable volumes and fall in mid-level percentiles for their respective denominators, suggesting the practice uses a standard mix of supportive agents alongside primary oncology therapy rather than an unusually broad or novel drug portfolio.

There are moderate-volume, high-cost items outside the top drug that contribute meaningfully to revenue: 99215 and 99214 together account for over 11% of Medicare revenue ($83.2K and $67.8K respectively), indicating substantial revenue from high-complexity and moderate-complexity office visits in addition to drug administration. This combination points to an integrated visit-plus-infusion workflow where evaluation and management visits are a material revenue component.

Provider tenure is long-standing: the NPI was enumerated on 2005-05-24 (~21 years ago), indicating sustained presence in the Medicare program and likely an established local practice in Bend, OR. That tenure, combined with concentrated oncology drug billing, suggests an experienced oncology clinician with an established outpatient infusion operation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

50 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,400	$40	$877.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	620	$140	$83.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	750	$90	$67.8K
J0897	Injection, denosumab, 1 mg	3,480	$20	$62.6K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	8,020	$10	$48.1K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	300	$110	$33.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	310	$100	$31.7K
J1439	Injection, ferric carboxymaltose, 1 mg	26,250	$1	$26.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	320	$80	$26.2K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	70	$160	$11.2K

Showing 1–10 of 50

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 50 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

William Schmidt — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

50 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	30	8,700	$40	$430.9K
J0897	25	70	2,400	$20	$78.3K
Q5111	1	10	300	$110	$33.4K
J2506	1	10	320	$80	$25.1K
J1439	3	10	19,130	$1	$20.1K
96413	10	90	150	$100	$18.2K
J9217	30	50	90	$130	$15.1K
99214	89	6,070	80	$70	$10.3K
Q5106	1	20	820	$10	$8.5K
J0185	2	20	5,140	$1	$7.2K

Showing 1–10 of 50

Related Providers

Other providers that share a Tax Identification Number (TIN) with William Schmidt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mainehealth	ME	General Acute Care Hospital	$0	$142.6M
Mainehealth	ME	Community/Behavioral Health Agency	$0	$115M
Mainehealth	ME	General Acute Care Hospital	$0	$70.7M
Mainehealth	ME	General Acute Care Hospital	$0	$40M
Mainehealth	ME	General Acute Care Hospital	$0	$31.5M
Mainehealth	ME	General Acute Care Hospital	$0	$22.7M
Mainehealth	ME	Rural Health Clinic/Center	$0	$16.7M
Bend Memorial Clinic PC	OR	Family Medicine Physician	$0	$11.7M
Mainehealth	ME	Multi-Specialty Clinic/Center	$0	$10.9M
Mainehealth	ME	Rural Health Clinic/Center	$0	$10M

Nearby Providers

Other providers in the same ZIP code as William Schmidt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ortc, LLC	OR	Substance Abuse Rehabilitation Facility	$747.3K	$16.2M
Telecare Mental Heatlh Service Of Oregon, Inc	OR	Mental Illness Community Based Residential Treatment Facility	$0	$12.8M
Pfeifer & Associates	OR	Community/Behavioral Health Agency	$0	$11.6M
Grants Pass Treatment Center	OR	Substance Abuse Rehabilitation Facility	$0	$9.5M
St. Charles Health System, Inc.	OR	Family Medicine Physician	$0	$8.6M
Deschutes County Oregon	OR	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$7.9M
Central Oregon Pediatric Associates	OR	Pediatrics Physician	$0	$7.2M
Bend Surgery Center LLC	OR	Ambulatory Surgical Clinic/Center	$4.8M	$1.7M
Adam Angeles	OR	Plastic and Reconstructive Surgery Physician	$6.5M	$0
Central Oregon Emergency Physicians LLC	OR	Emergency Medical Services (Emergency Medicine) Physician	$0	$5.2M

William Schmidt — Billing Profile & Reimbursement Data

Sign up for William Schmidt — Billing Profile & Reimbursement Data policy alerts

William Schmidt — Billing Profile & Reimbursement Data

Sign up for William Schmidt — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References